CD7 CAR-T treatment then stem cell transplant for CD7 leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent, with expected survival of more than 12 weeks
- Have relapsed or not fully responding CD7-positive acute leukemia (ALL or AML) after standard chemo, or after first/other treatments
- Be well enough to do daily activities (ECOG score 0–2) and have oxygen level above 92% without needing oxygen
- Have key organ function tests within limits (liver enzymes and bilirubin not too high, kidney function adequate, and pancreas enzymes not too high)
- Not be pregnant or breastfeeding, and use effective birth control for the required time during and after study treatment
- No seizure/major brain disease, and no active infections that are not under control
- Not have had certain cancer treatments too recently, and no planned stem cell transplant while in this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a new treatment made from your own immune cells (NK cells) that are modified to recognize and attack cancer cells with a marker called CD7. It is for people whose blood cancer has returned or not improved with other treatments.
This trial tests a new immune therapy called CD7 CAR-T cells for people with acute leukemia that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment is safe and can help control the leukemia.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial tests a treatment that uses your own immune cells (CAR-T) engineered to find and attack CD7 on T-cell lymphoma cells, followed by a stem cell transplant to rebuild your immune system. It is for people with certain types of T-cell lymphoma that have come back or not responded to standard treatments.
This trial tests a special immune cell therapy (CAR-T) that targets CD7, a protein found on T-cell leukemia and lymphoma cells. It is for people who have very small amounts of cancer remaining after a stem cell transplant.
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.